Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.30 |
| ▸ | PGR | P06401 | 2/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987097 | 0.88 | PPARG (0.41) | CPB2PPARGSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4984253 | 0.87 | CPB2 (0.32) | CPB2PPARGSMN1; SMN2SLC1A3SLC1A2 | |
| SCHEMBL4985190 | 0.86 | CPB2 (0.35) | CPB2PPARGSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4994542 | 0.85 | CPB2 (0.35) | CPB2PPARGSMN1; SMN2SLC1A3SLC1A2 | |
| SCHEMBL4991583 | 0.85 | GRIK1 (0.33) | CPB2PPARGGRIK1 | |
| SCHEMBL4991134 | 0.84 | NR3C1 (0.40) | CPB2PPARGPPARDPPARANR3C1 | |
| SCHEMBL4991353 | 0.84 | TAAR1 (0.41) | CPB2PPARGSMN1; SMN2PPARDPPARA | |
| SCHEMBL4992913 | 0.83 | CPB2 (0.35) | CPB2PPARGSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4986612 | 0.82 | PPARG (0.48) | CPB2PPARGSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4984618 | 0.80 | CPB2 (0.34) | CPB2PPARGSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | CPB2 1747/4885PPARG 1820/4885SMN1; SMN2 1368/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | CPB2 1342/4885PPARG 1405/4885SMN1; SMN2 1347/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CPB2 1460/4885PPARG 1828/4885SMN1; SMN2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.